TY - JOUR
T1 - Rebamipide-induced downregulation of phospholipase D inhibits inflammation and proliferation in gastric cancer cells
AU - Kang, Dong Woo
AU - Min, Gyesik
AU - Park, Do Yoon
AU - Hong, Ki Whan
AU - Min, Do Sik
PY - 2010
Y1 - 2010
N2 - Rebamipide a gastroprotective drug, is clinically used for the treatment of gastric ulcers and gastritis, but its actions on gastric cancer are not clearly understood. Phospholipase D (PLD) is overexpressed in various types of cancer tissues and has been implicated as a critical factor in inflammation and carcinogenesis. However, whether rebamipide is involved in the regulation of PLD in gastric cancer cells is not known. In this study, we showed that rebamipide significantly suppressed the expression of both PLD1 and PLD2 at a transcriptional level in AGS and MKN-1 gastric cancer cells. Downregulation of PLD expression by rebamipide inhibited its enzymatic activity. In addition, rebamipide inhibited the transactivation of nuclear factor kappa B (NFκB), which increased PLD1 expression. Rebamipide or PLD knockdown significantly suppressed the expression of genes involved in inflammation and proliferation and inhibited the proliferation of gastric cancer cells. In conclusion, rebamipide-induced downregulation of PLD may contribute to the inhibition of inflammation and proliferation in gastric cancer.
AB - Rebamipide a gastroprotective drug, is clinically used for the treatment of gastric ulcers and gastritis, but its actions on gastric cancer are not clearly understood. Phospholipase D (PLD) is overexpressed in various types of cancer tissues and has been implicated as a critical factor in inflammation and carcinogenesis. However, whether rebamipide is involved in the regulation of PLD in gastric cancer cells is not known. In this study, we showed that rebamipide significantly suppressed the expression of both PLD1 and PLD2 at a transcriptional level in AGS and MKN-1 gastric cancer cells. Downregulation of PLD expression by rebamipide inhibited its enzymatic activity. In addition, rebamipide inhibited the transactivation of nuclear factor kappa B (NFκB), which increased PLD1 expression. Rebamipide or PLD knockdown significantly suppressed the expression of genes involved in inflammation and proliferation and inhibited the proliferation of gastric cancer cells. In conclusion, rebamipide-induced downregulation of PLD may contribute to the inhibition of inflammation and proliferation in gastric cancer.
UR - http://www.scopus.com/inward/record.url?scp=77957350064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957350064&partnerID=8YFLogxK
U2 - 10.3858/emm.2010.42.8.056
DO - 10.3858/emm.2010.42.8.056
M3 - Article
C2 - 20625243
AN - SCOPUS:77957350064
SN - 1226-3613
VL - 42
SP - 554
EP - 564
JO - Experimental and Molecular Medicine
JF - Experimental and Molecular Medicine
IS - 8
ER -
